Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Background: We performed an individual patient data meta-analysis to examine the impact of first-generation epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor (TKI) therapy on overall survival (OS) in advanced non-small cell lung cancer (NSCLC). Methods: Data from trials comparing E...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lee C., Davies L., Wu Y., Mitsudomi T., Inoue A., Rosell R., Zhou C., Nakagawa K., Thongprasert S., Fukuoka M., Lord S., Marschner I., Tu Y., Gralla R., Gebski V., Mok T., Yang J.
Format:	Journal
Published:	2017
Online Access:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85027265241&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/40447
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Chiang Mai University

Similar Items

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
by: Chee Khoon Lee, et al.
Published: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
by: Chee Khoon Lee, et al.
Published: (2018)

Lung cancer response to gefitinib, then erlotinib, then gefitinib again
by: Wong, A.S., et al.
Published: (2014)

EGFR Mutant Structural Database: Computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
by: Ma, L, et al.
Published: (2020)

Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments
by: Wang D.D., et al.
Published: (2019)

EFFICACY OF GEFITINIB AND ERLOTINIB IN NON-SMALL-CELL LUNG CARCINOMA
by: Afrita Amalia Laitupa, -, et al.
Published: (2019)

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
by: Wong, A.S., et al.
Published: (2014)

Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
by: Tony Mok, et al.
Published: (2018)

Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
by: Tony Mok, et al.
Published: (2018)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
by: Natthaporn Sueangoen, et al.
Published: (2020)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
by: Fukuoka M., et al.
Published: (2017)

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
by: Chee Khoon Lee, et al.
Published: (2018)

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
by: Chee Khoon Lee, et al.
Published: (2018)

EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib-letter
by: Voon, P.J., et al.
Published: (2014)

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
by: Yeo, W.-L., et al.
Published: (2011)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
by: Masahiro Fukuoka, et al.
Published: (2018)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
by: Suresh S. Ramalingam, et al.
Published: (2020)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
by: Suresh S. Ramalingam, et al.
Published: (2020)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Wu Y., et al.
Published: (2017)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
by: Tony S. Mok, et al.
Published: (2018)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
by: Tony S. Mok, et al.
Published: (2018)

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
by: Ku, G.Y., et al.
Published: (2016)

EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth
by: Assiddiq, B.F., et al.
Published: (2014)

PERBANDINGAN RESPONS TERAPI GEFITINIB PADA PASIEN KPKBSK DENGAN EGFR MUTASI EXON 19 DAN EXON 21
by: Titin Sholihah Agustina, NIM011180901
Published: (2017)

PERBANDINGAN EFIKASI GEFITINIB DAN ERLOTINIB PADA PASIEN KANKER PARU JENIS KARSINOMA BUKAN SEL KECIL DI POLI ONKOLOGI SATU ATAP RS DR SOETOMO SURABAYA
by: Afrita Amalia Laitupa
Published: (2019)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Yi Long Wu, et al.
Published: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Yi Long Wu, et al.
Published: (2018)

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
by: Scagliotti G.V., et al.
Published: (2014)

Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
by: Reungwetwattana T.
Published: (2023)

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
by: Cho B.C.
Published: (2023)

The role of chemotherapy in cholangiocarcinoma
by: Thongprasert S.
Published: (2014)

The role of chemotherapy in cholangiocarcinoma
by: S. Thongprasert
Published: (2018)

Erlotinib in previously treated non-small-cell lung cancer
by: Frances A. Shepherd, et al.
Published: (2018)

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial
by: Giorgio V. Scagliotti, et al.
Published: (2018)

Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report
by: Chaichana Chantharakhit
Published: (2019)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
by: Wu Y.-L., et al.
Published: (2014)

SYNTHESIS OF QUINAZOLINE DERIVATIVES AS GEFITINIB INTERMEDIATES
by: Auliya Hafizah, Raysa

Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry
by: Wang, L.-Z., et al.
Published: (2014)

Testicular Seminoma: Correlation Between Staging and Chemotherapy Response, Two Years Overall Survival Rate
by: Ida Bagus Putra Pramana, et al.
Published: (2019)

Lung cancer working group report
by: Saijo N., et al.
Published: (2017)